Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?
Longer Term Data Ready Soon
Executive Summary
The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.
You may also be interested in...
GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow
Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.
Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.